Vyome therapeutics to list on nasdaq as HIND after reshape merger

CAMBRIDGE, Mass. - Vyome Therapeutics, Inc. announced Tuesday that Nasdaq has approved its listing following the completion of its previously announced merger with ReShape Lifesciences (NASDAQ:RSLS), which currently trades at $2.37 with a market capitalization of $5.7 million. According to InvestingPro data, RSLS has experienced significant volatility, with the stock down over 96% in the past six months. The company will begin trading under the name Vyome Holdings, Inc. and the ticker symbol "HIND" on Friday, August 15, 2025.

In conjunction with the merger, ReShape’s Board of Directors has declared a 1-for-4 reverse stock split of the company’s common stock, also effective August 15. Each four shares of issued and outstanding common stock will be converted into one share, with a new CUSIP number of 92943X104. The company’s financial health score is currently rated as ’WEAK’ by InvestingPro, which offers comprehensive analysis through its Pro Research Reports, available for over 1,400 US stocks.

"Nasdaq’s approval is right on track and now we are marching forward to ring the bell on our planned listing date this Friday," said Krishna Gupta, Chairman of Vyome, in a press release statement.

Vyome Therapeutics describes itself as a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in U.S. and global markets. The company is based in Cambridge, Massachusetts, and positions itself across what it calls the "US-India innovation corridor."

According to the company’s founder Shiladitya Sengupta, who is also an Associate Professor of Medicine at Harvard Medical School, Vyome’s clinical-stage assets focus on unmet needs in the immuno-inflammatory space.

The reverse stock split will not impact the post-merger ownership allocations between ReShape and Vyome shareholders in the transaction.

In other recent news, ReShape Lifesciences announced a significant leadership transition as Vyome Therapeutics prepares to take control and rename the company Vyome Holdings, Inc. This change is set to occur on August 15, 2025, when the company will begin trading under a new ticker symbol. Meanwhile, ReShape Lifesciences has entered into a promissory note agreement with Vyome, providing a $200,000 loan to support the merger process. If the merger is completed before the repayment deadline, Vyome will not be required to repay the loan. Additionally, ReShape Lifesciences is set to receive a new patent for its intragastric balloon system, enhancing its intellectual property portfolio. The company also announced it has regained compliance with Nasdaq’s stockholders’ equity requirement, securing its continued listing on the exchange. In a move to improve financial efficiency, ReShape Lifesciences has implemented a strategic workforce reduction, which is expected to save over $750,000 annually. Despite these changes, the company will maintain its sales and marketing efforts, focusing on digital campaigns and international expansion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.